Oncology (ONC)

P-005 - A POST-HOC ANALYSIS OF POTENTIAL ETHNIC DIFFERENCES IN LORLATINIB PHARMACOKINETICS IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

P-006 - COMPARISON OF UTOMILUMAB IMMUNOGENICITY IN PATIENTS WITH ADVANCED CANCER.

P-022 - TUMOR TARGETED TYPE I INTERFERON ENGAGES DENDRITIC CELLS TO ENHANCE THE ANTITUMOR RESPONSE TO RADIOTHERAPY.

P-025 - AN OPEN-LABEL STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF SOTORASIB ADMINISTERED AS TABLETS OR AS A WATER DISPERSION IN HEALTHY SUBJECTS.

P-026 - AN OPEN-LABEL STUDY TO EVALUATE THE DRUG-DRUG INTERACTION EFFECT OF ITRACONAZOLE, A STRONG CYP3A4 AND P-GP INHIBITOR, ON THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS.

P-027 - AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS.

P-030 - THE POTENTIAL ANTI-EMETIC EFFECT OF COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT PEPTIDE ON CISPLATIN-INDUCED EMESIS IN SUNCUS MURINUS.

P-031 - CLINICAL PHARMACOLOGY CONSIDERATIONS FOR ANTIBODY-DRUG CONJUGATES (ADCS) IN ONCOLOGY: A REVIEW OF RECENT APPROVALS.

P-032 - POPULATION PHARMACOKINETICS OF ZIMBERELIMAB (AB122) AND DOSE JUSTIFICATION BY MODEL INFORMED DRUG DEVELOPMENT (MIDD) APPROACH.

P-048 - EVALUATION OF THE SINGLE DOSE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF GS-3583, A FLT3 AGONIST FC FUSION PROTEIN, IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS.

P-053 - EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

P-056 - ASSOCIATIONS OF HLA-C*01:02 AND HLA-B*46:01 WITH REGORAFENIB-INDUCED ERYTHEMA MULTIFORME IN JAPANESE PATIENTS WITH COLORECTAL CANCER.

P-064 - A FIRST-IN-HUMAN, DOSE-ESCALATION, DRUG-INTERACTION, AND FOOD-EFFECT STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF INCB106385, A SELECTIVE ADENOSINE RECEPTOR ANTAGONIST, IN HEALTHY ADULTS.

P-078 - PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF ABBV-321, AN EGFR-TARGETING ADC, IN PATIENTS WITH ADVANCED SOLID TUMORS.

P-102 - A MECHANISTIC PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODEL OF QUEMLICLUSTAT (AB680), A SMALL-MOLECULE INHIBITOR OF CD73, IN HEALTHY VOLUNTEERS AND PATIENTS WITH GASTROINTESTINAL MALIGNANCIES.

P-118 - A PHASE I STUDY TO EVALUATE ABSOLUTE BIOAVAILABILITY AND ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION (ADME) OF SAVOLITINIB IN HEALTHY MALE VOLUNTEERS.

P-126 - POPULATION PHARMACOKINETICS (POPPK) MODELING AND EXPOSURE-RESPONSE (E-R) RELATIONSHIP ANALYSES OF CEMIPLIMAB (CEMI) IN PATIENTS (PTS) WITH RECURRENT OR METASTATIC CERVICAL CANCER (R/M CC).

P-127 - CLINICAL PHARMACOLOGY LEARNINGS FROM FDA-APPROVED HEMATOLOGY-ONCOLOGY THERAPEUTICS (ACROSS MODALITIES & ACROSS DISEASE INDICATIONS): LAST 5 YEARS.

P-130 - MATHEMATICAL MODELS FOR EARLY DETECTION OF RELAPSE IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE.

P-136 - ALTERNATIVE DOSING SCHEDULES FOR THERAPEUTIC WINDOW OPTIMIZATION FOR THE ATAXIA TELANGIECTASIA & RAD3-RELATED PATHWAY (ATR) INHIBITOR ELIMUSERTIB IN PATIENTS WITH ADVANCED SOLID TUMORS: M&S -BASED EXPLORATION USING PHASE I DATA.

P-150 - NIVOLUMAB PHARMACOKINETICS WHEN ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH SOLID TUMORS: POPULATION PHARMACOKINETIC ANALYSIS FROM CHECKMATE 8KX.

P-171 - IMMUNE CHECKPOINT EXPRESSION IN ACUTE LEUKEMIA IS INFLUENCED BY DAUNORUBICIN TREATMENT DOSE.

P-173 - EVALUATION OF MORNING VERSUS EVENING DOSING OF IPATASERTIB, AN AKT INHIBITOR TO MITIGATE IPATASERTIB INDUCED GLUCOSE CHANGES.

P-179 - PARP1 EXPRESSION IS A STRONG PROGNOSTIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANT.

P-180 - MODEL-BASED POPULATION PHARMACOKINETIC ANALYSIS OF NIVOLUMAB AS ADJUVANT TREATMENT IN PATIENTS WITH ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER (CHECKMATE-577).

P-198 - ABSENCE OF ETHNIC DIFFERENCES IN PHARMACOKINETIC PROFILE OF ENFORTUMAB VEDOTIN BETWEEN JAPANESE AND NON-JAPANESE PATIENTS.

P-199 - EVALUATION OF QTC INTERVAL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA FOLLOWING ENFORTUMAB VEDOTIN ADMINISTRATION.

P-209 - MODEL-INFORMED CLINICAL PHARMACOLOGY (CP) PROFILE OF A NOVEL FIXED-DOSE COMBINATION (FDC) OF RELATLIMAB AND NIVOLUMAB IN PATIENTS WITH SOLID TUMORS.

P-211 - CLINICAL PHARMACOLOGY CHARACTERIZATION OF AMG 119, A CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY TARGETING DELTA-LIKE LIGAND 3 (DLL3), IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (R/R SCLC).

PT-006 - HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS.

PT-006 - HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS.

LB-001 - MACHINE LEARNING (ML) METHODS FOR PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) PREDICTION: RE-ANALYSIS OF JAVELIN HEAD AND NECK 100 DATA.

LB-002 - SHORT DAILY DISCONNECT OF FIRST-IN-CLASS BiTE® BLINATUMOMAB CONTINUOUS INTRAVENOUS INFUSION (cIV) TO IMPROVE PATIENT QUALITY OF LIFE WHILE MINIMIZING IMPACT ON EXPOSURE AND EFFICACY IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS.